SelectScience
Join Free
Accelerating Science
NewsClinical Diagnostics

New data published from Women & Infants Hospital demonstrate utility of predictive immune modeling in ovarian cancer

Cofactor Genomics

This study offers new insights into high grade serous ovarian cancer that have the potential to make an impact in how patients are treated in the future

25 Mar 2021
Diane Li
Assistant Editor

Industry news

Cofactor Genomics, the company bridging the precision medicine gap, has announced new data published in Frontiers in Oncology by Women & Infants Hospital of Rhode Island. The data highlight the utility of Cofactor’s Predictive Immune Modeling technology in elucidating the immune landscape of epithelial ovarian cancer (EOC) for immunotherapy development, and to identify prognostic indicators of response to frontline chemotherapy.

EOC is the most lethal of all gynecological malignancies, with more than 21,000 diagnoses and almost 14,000 deaths anticipated from the disease in the United States in 2020. Currently, several EOC clinical trials center upon immunotherapy; however, while melanoma and non-small cell lung cancer (NSCLC) patients have seen a great benefit from targeting immune checkpoint inhibitors, such cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or programmed cell death protein 1 (PD-1), EOC patients have only exhibited response rates of 10 to 15 percent. Despite these poor response rates, evidence suggests that EOC is an immunogenic cancer, and in the paper, the team led by Jennifer Ribeiro, Ph.D., at Women & Infants Hospital outlined how these results lay the foundation for the development of better immunotherapy agents.

The primary investigator on the study, Dr. Ribeiro, stated, “This study offers new insights into high grade serous ovarian cancer that have the potential to make an impact in how patients are treated in the future. Using the ImmunoPrism platform, we have shown that immunological signatures are indeed related to patient outcomes in ovarian cancer.”

In the study, the authors utilized the Cofactor Genomics ImmunoPrism® platform to evaluate a cohort of high grade serous ovarian cancer (HGSOC) tumors to identify an immune-related gene expression model that may serve as a prognostic indicator of response to frontline chemotherapy. They found that the immunological markers CTLA-4, LAG-3, and Treg immune cells are more abundant in HGSOC patients with longer progression-free survival (PFS). Moreover, they investigated which immunological features in a tumor led to improved outcomes, which represent opportunities for novel immunotherapeutic approaches. The study also revealed that ICOS was significantly more highly expressed in patients with longer PFS, and strongly correlated with CTLA-4, PD-1, and specific subsets of immune cell infiltration. The results from the tumor cohort were confirmed using The Cancer Genome Atlas (TCGA) ovarian cancer dataset where high ICOS and LAG-3 levels were also significantly associated with longer survival.

The study builds on Cofactor’s previously presented work using its Predictive Immune Modeling technology to identify novel immune signals in other disease indications, including sarcoma, non-small cell lung cancer (NSCLC), and recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC). The company has also announced a list of disease targets for diagnostic development and is current recruiting clinical partners: https://cofactorgenomics.com/clinical/

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

Links

Cofactor GenomicsCompany website

Tags

HematologyIn Haematology / Hematology, complete blood cell counts (or full blood counts) are obtained using automated blood count analyzers to enumerate blood cell types.  Hematology also encompasses haemostasis and coagulation, thrombophilia and hemophilia, plasma viscosity and ESR analysis, hemoglobinopathies, cell morphology and haematinic measurement.ImmunologyImmunological techniques measure and characterize immune responses. Immunology kits and analysis systems often use techniques such as ELISA, radioimmunoassay (RIA) and immunodiffusion assays, Immunohistochemistry, and flow cytometry. Immunologists use equipment such as flow Cytometers, plate readers, plate washers and fluorescent microscopes.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Cancer CellsCancer cells are abnormal cells that divide uncontrollably, leading to the formation of tumors and the spread of cancer. Studying cancer cells is crucial for developing new treatments and understanding tumor biology. Explore cancer cell research products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Cancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Ovarian CancerImmunotherapyImmunotherapy is a treatment approach that utilizes the body�s immune system to fight diseases, especially cancer. It includes therapies such as monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapy. Immunotherapy is a rapidly growing area of research in oncology and autoimmune diseases. Browse our peer-reviewed product directory to find the best immunotherapy tools, compare products, check reviews, and get pricing directly from manufacturers.Cancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles